Symptoms and General Pathology

All Conditions

Neoplasms

Nervous System Diseases

Immune System Diseases

Diseases and Abnormalities at or Before Birth

Rare Diseases

Syndrome

Lambert-Eaton Myasthenic Syndrome

Myasthenic Syndromes, Congenital

Myasthenia Gravis

Paraneoplastic Syndromes

Paraneoplastic Syndromes, Nervous System

Nervous System Neoplasms

Autoimmune Diseases

Autoimmune Diseases of the Nervous System

Neurodegenerative Diseases

Neuromuscular Junction Diseases

Neuromuscular Diseases

Genetic Diseases, Inborn

Lambert Eaton Myasthenic Syndrome

Congenital Myasthenic Syndromes

Reproductive Control Agents

Respiratory System Agents

All Drugs and Chemicals

Albuterol

Bronchodilator Agents

Anti-Asthmatic Agents

Tocolytic Agents

Adrenergic Agents

Adrenergic beta-Agonists

Adrenergic Agonists

Neurotransmitter Agents

4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.

Andrew G Engel, MD

The study tests the notion that patients suffering from certain types of congenital myasthenic syndromes are benefitted by the use of Albuterol at doses used in clinical practice.

The aim of the proposal is to evaluate the effects of albuterol, an adrenergic agonist, in the treatment of congenital myasthenic syndromes (CMS). Over the past 2 decades I found that some CMS patients refractory to or worsened by cholinergic agonists, namely those suffering from defects in acetylcholinesterase (AChE) or Dok-7, respond to ephedrine, a medication used for over half-a-century in the treatment of autoimmune myasthenia gravis. After ephedrine became unavailable, I treated the same type of patients with albuterol in doses ranging from 4 mg daily to twice daily for adults; the dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily. Evaluation of the effects of the medications are based on the Table shown below.

Name:

Mayo Clinic no:

Date of this report: (dd/mm/yyyy):

Before taking Albuterol ER On Albuterol (date of this report)

* Current daily dose of albuterol:

Dates when started (d/m/year) Daily dose Distance in feet walked without stopping to rest Number of steps climbed without stopping to rest Difficult to sit up from lying on back\* Difficult to rise from sitting\* Difficult to speak or swallow\* Shortness of breath on exertion\* Shortness of breath at night\* Weakness of arm or hand muscles \* Weakness of leg or foot muscles\*

\*Rate as mild, moderate, severe Describe below any additional changes in your condition such as arm elevation time, number of deep knee bends before having to stop, or in activities of daily living relevant to the effects of the treatment. Also indicate any unwanted side effects of the medication. Continue on other side or separate page if necessary. Return this questionnaire to Dr. Andrew Engel (email:schaefer.cleo@mayo.edu) ,after treatment with albuterol for 1 month and then monthly thereafter, or mail to Dr. Andrew Engel, Department of Neurology, Mayo Clinic, Rochester, MN 55905.

Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes

The primary outcome measures pertain to evaluating the improvement in the patient's strength

Mayo Clinic

Respiratory Tract (Lung and Bronchial) Diseases

Blood and Lymph Conditions

Respiratory Aspiration

Lymphangioleiomyomatosis

Lymphangiomyoma

Neoplasms by Histologic Type

Perivascular Epithelioid Cell Neoplasms

Neoplasms, Connective and Soft Tissue

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

2 puffs of Metered Dose inhaler for Bronchodilation

albuterol inhaler

Albuterol administered by nebulization will produce a greater increase in FEV1

albuterol nebulizer

Tatyana Worthy, R.N.

Joel Moss, M.D.

Background:

- Lymphangioleiomyomatosis (LAM) is a rare type of lung disease that occurs almost exclusively in women. In LAM, muscle tissue grows in the lungs and starts to block the flow of air. It is a progressive disease, and in severe cases may require a lung transplant. One possible treatment to improve breathing in people with LAM is inhaled albuterol. Albuterol can be given in a metered dose inhaler (MDI) or with a nebulizer. Researchers want to compare these methods to see which method best improves lung function in women with LAM.

Objectives:

- To see whether a nebulizer or MDI can better improve lung function in women with LAM.

Eligibility:

- Women at least 18 years of age who have impaired lung function because of LAM.

Design:

* Participants will be screened with a physical exam and medical history. No lab tests will be needed for this study.
* Participants will have a 3-day overnight stay at the National Institutes of Health. Those who are using long-acting inhalers will have to stop taking these drugs 1 week before the study.
* Participants will receive either the nebulizer or two or four puffs of the inhaler. Four puffs of albuterol is a higher dose than is normally prescribed, and is being tested on this study.
* Participants will have each treatment around the same time of day on each of the 3 days. Before and after taking the albuterol, participants will have lung function tests.

We have reported that approximately one third of patients with lymphangioleiomyomatosis (LAM) who have airflow obstruction respond to bronchodilators such as albuterol, a Beta2-adenergic receptor agonist, with an increase in forced expiratory flow in one second (FEV1) of 12% and 200 ml above baseline values. Others however, have questioned these findings, reporting instead, a low rate of response of only six percent. Contrasting with our study, in this study albuterol was administered with a metered dose inhaler whereas in ours it was given by nebulizer. We propose to measure changes in lung function after administration of albuterol, respectively by metered inhaler and nebulizer, for 3 consecutive days in 100 LAM subjects. Our hypothesis is that albuterol administered by nebulization will produce a greater increase in FEV1 than two puffs of inhaled albuterol. If this hypothesis is confirmed, then we may recommend that patients with LAM and airflow obstruction use as a method of drug administration a nebulizer, rather than a metered dose inhaler.

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis

Bronchodilator Effects of Nebulized Versus Inhaled Albuterol in Subjects With Lymphangioleiomyomatosis

Greater improvement in lung function with nebulized albuterol.

National Heart, Lung, and Blood Institute (NHLBI)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes	NCT01203592	Congenital Myas...	Albuterol	2 Years -	Mayo Clinic
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis	NCT01799538	Lymphangioleiom...	albuterol inhal... albuterol nebul... PFT	18 Years - 100 Years	National Institutes of Health Clinical Center (CC)
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis	NCT01799538	Lymphangioleiom...	albuterol inhal... albuterol nebul... PFT	18 Years - 100 Years	National Institutes of Health Clinical Center (CC)

Spots Global Cancer Trial Database for albuterol

Every month we try and update this database with for albuterol cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for albuterol

Every month we try and update this database with for albuterol cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for albuterol cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.